Prenatal Genetic Screening: Checklist for At-Risk Families

More than 450 distinct inborn errors of immunity have now been catalogued in the medical literature, and yet the diagnostic toolkit for catching them before birth is narrower than the consumer-facing materials imply. In my experience reviewing reproductive planning consults from the immunology side, the two failure modes I see most often are these: families assuming a clean family history rules out risk, and families treating non-invasive prenatal screening as a substitute for the diagnostic procedures that actually produce a definitive answer. Both assumptions collapse under scrutiny. A targeted prenatal workup for an at-risk family is a layered process — confirmed molecular diagnosis in an index case, mapped inheritance mechanics, a defined gestational window, and an honest reckoning with procedural risk. The checklist below walks through each layer as I'd run it in the clinic.

Establishing the Genetic Foundation: Family History and Index Cases

Before any instrument goes near a pregnancy, the molecular groundwork has to be solid. A prenatal diagnosis is only as reliable as the variant being tested for. Without a characterized pathogenic variant in an affected family member — the index case — you're screening blind, and a "negative" result from that kind of fishing expedition is meaningless.

What this looks like in practice:

• Confirm the diagnosis in the index case with documented genetic sequencing, not clinical impression alone. Phenocopies are real across the PID spectrum; two unrelated genotypes can produce overlapping clinical pictures, and the prenatal test has to be designed against the actual variant, not the suspected syndrome.
• Identify the specific pathogenic variant (or variants) at the sequence level. Most PIDs follow autosomal recessive inheritance, which means both alleles typically need to be characterized before prenatal interpretation is meaningful. A "carrier" report on one allele is half the information.
• Map the pedigree with sex and outcomes for each relative. X-linked disorders follow a transmission logic that directly determines whether a male or female fetus is at meaningful risk — that logic cannot be reconstructed without an accurate family tree.
• Verify that the lab performing the prenatal test can specifically interrogate your family's known variant(s). A panel that doesn't include the family's mutation is not a negative test; it is an uninformative one.

Without an index case and a characterized variant, prenatal testing for a specific PID is fishing in the dark.

Inheritance Patterns in Inborn Errors of Immunity

Most primary immunodeficiencies do not behave like the dominant Mendelian traits that family members often expect. Two inheritance modes dominate the clinical landscape:

• Autosomal recessive. The fetus must inherit a pathogenic variant from both parents, who are typically unaffected carriers. Recurrence risk for a known carrier couple is 25% per pregnancy. This pattern accounts for a substantial fraction of severe combined immunodeficiency cases outside the X-linked subtype.
• X-linked recessive. The pathogenic variant sits on the X chromosome. Carrier mothers transmit to roughly half of sons (affected) and half of daughters (carriers). X-linked SCID is the most cited example in prenatal counseling for immunodeficiency.

A smaller fraction of PIDs follow autosomal dominant inheritance, where transmission risk is 50% per pregnancy from an affected parent. The point for the checklist: inheritance pattern is not a footnote. It determines whether a fetus of a given sex is at meaningful risk at all, which determines whether invasive testing is being deployed to answer a question that has a yes-or-no answer.

Diagnostic Windows: Comparing CVS and Amniocentesis

This is where gestational timing meets clinical decision-making. The two diagnostic procedures — the ones that produce a definitive genetic answer, not a probabilistic one — operate in different windows and carry different risk profiles:

The trade-off between the two is not "better versus worse" — it is "earlier answer versus later answer with a different risk profile." Families with a confirmed autosomal recessive or X-linked disorder and a known variant often favor CVS for the earlier result, accepting the procedural risk in exchange for more reproductive options and a shorter period of uncertainty. Families who present later in gestation or who weight the risk calculus differently may opt for amniocentesis.

Where cell-free fetal DNA screening (NIPT) fits — and where it doesn't: NIPT can flag aneuploidies and some large structural variants with reasonable sensitivity in general obstetric use, but it is not validated as a single-test screen for the monogenic PID spectrum, and a negative NIPT does not rule out an inborn error of immunity. The distinction between screening and diagnosis is the entire game here, and conflating the two is the most common counseling error I see.

Procedural Risks and Clinical Decision-Making

The 1-in-500 pregnancy loss estimate for CVS is not a marketing line — it is a cohort-derived figure, and centers with high operator volume tend to publish lower complication rates. Several factors shift the practical risk calculation:

• Operator and center volume. High-volume centers performing invasive prenatal procedures frequently report loss rates in the range of 1 in 1,000 or better; lower-volume centers may track closer to the 1-in-500 figure. Where the procedure is performed matters as much as which procedure is performed.
• Gestational age at sampling. Within the CVS window, earlier sampling carries a different risk profile than later sampling, and the difference is not negligible.
• Maternal factors. BMI, uterine anatomy, and prior pregnancy complications all shift the calculus. Counseling that ignores these is generic counseling.
• Comparative framing. The relevant question is not "is 1 in 500 small in the abstract?" — it is "is 1 in 500 smaller than the recurrence risk for the specific disorder we're testing for?" For autosomal recessive PIDs with 25% recurrence, the answer is usually yes. For X-linked carriers facing a 50% chance of an affected male fetus, the calculus is closer, and the family conversation is correspondingly harder.

A negative NIPT is not a negative diagnostic result. Where family history warrants invasive testing, NIPT does not substitute for it.

De Novo Variants and the Limits of Family History

This is where I see the most counseling breakdowns. A meaningful fraction of severe PIDs arise from de novo variants — genetic changes present in the fetus but not inherited from either parent. The parents are not carriers; the pedigree is empty; the affected child is the first case in the family. No amount of family-history-taking will predict a de novo event.

What this means for the checklist:

• A negative family history reduces prior probability; it does not set it to zero. For disorders with a documented de novo rate, the residual risk is real even with a clean pedigree.
• De novo events are not predictable by parental carrier screening in most cases. They typically arise during gametogenesis or early embryogenesis and are not detectable by sequencing the parents.
• For families with no prior affected child and no characterized variant, the targeted prenatal diagnostic pathway described above does not apply directly. There is no variant to test for. In these scenarios, newborn screening for SCID — typically via TREC assay — is the relevant downstream intervention, not targeted prenatal diagnosis.

If your family history is genuinely empty and you are not from a population with elevated carrier frequency for a specific PID, the appropriate framework is often general-population newborn screening, not targeted prenatal diagnosis. That distinction is the part most consumer-facing prenatal materials flatten, and it matters.

Pre-Test Checklist for At-Risk Families

A practical sequence to bring into your genetics consultation:

1. Confirm a molecular diagnosis in the index case. Bring the sequencing report, not just a clinical diagnosis label.

2. Identify the specific pathogenic variant(s) and inheritance pattern. For autosomal recessive conditions, both alleles need to be on the table.

3. Document the pedigree with sex, affected status, and pregnancy outcomes for each relative on the relevant side of the family.

4. Verify that the prenatal diagnostic lab can interrogate your family's known variant(s). Confirm the methodology, the targeted assay, and the expected turnaround time in writing.

5. Discuss gestational timing with maternal-fetal medicine and clinical genetics together, not sequentially. The CVS-versus-amniocentesis decision depends on how far along you are at presentation, the operator volume at the performing center, and your family's tolerance for procedural risk.

6. Clarify what NIPT can and cannot tell you before accepting it as part of the workup. It is a screening tool, not a diagnostic one for monogenic PIDs.

7. Plan for the result scenarios — confirmed affected fetus, unaffected carrier, and inconclusive or variant-of-uncertain-significance findings. Pre-procedure genetic counseling is not optional, and it should not be scheduled for after the result.

Final Verdict

For families with a confirmed PID in the pedigree, the prenatal diagnostic pathway is well-defined: characterize the variant, establish the inheritance pattern, choose the procedure that fits your gestational window and risk tolerance, and treat NIPT as a screening adjunct rather than a substitute. The 450-plus disorders in the IEI catalog do not behave uniformly, and the workup for a family with X-linked SCID differs materially from the workup for a family with an autosomal recessive combined immunodeficiency. Generic prenatal panels will not catch what a targeted variant analysis will. Do the molecular work first; then bring the data to the diagnostic team.

For families without a known family history, the prenatal diagnostic calculus is fundamentally different, and newborn screening for SCID — not targeted prenatal diagnosis — is often the more appropriate safety net. The workup that protects a subsequent pregnancy is not the same workup that protects a current newborn, and conflating them produces the kind of false reassurance that no family needs to walk out of a consult with.